Hormones and Aging: Why How You Feel Is Part of How You Look

Hormones are chemical signals. They influence how tissues communicate, how the body uses energy, how we sleep, how we maintain bone and muscle, how sexual function works, and how skin and hair behave. When those signals change, patients often notice the effect before they know how to describe it.

They may say they no longer feel like themselves. Sleep is lighter. Recovery is slower. Body composition changes despite familiar habits. Libido shifts. Hot flashes appear. Energy becomes less predictable. Skin feels drier or thinner. Those symptoms deserve to be taken seriously, but they do not all prove a hormone deficiency.

Many medical and lifestyle problems can produce the same complaints. The responsible approach is not to assume hormones are the answer. It is to determine whether hormonal change is part of the picture, what else may be contributing, and whether treatment offers more benefit than risk for that individual.

Laboratory values are important, but they are not grades. A number can fall within a population reference range and still require interpretation in the context of symptoms, age, menstrual status, medications, timing, and the way the test was measured. A value outside a range does not automatically mean treatment is needed.

In perimenopause, hormone levels can fluctuate substantially from day to day and month to month. A single estradiol or follicle-stimulating hormone value may not capture the entire transition. The history and menstrual pattern often tell us more, while laboratory testing helps when the presentation is atypical, the diagnosis is uncertain, or another condition needs to be excluded.

In men, testosterone should not be diagnosed from one random afternoon level. Current endocrine guidance requires compatible symptoms and consistently low morning measurements, generally confirmed on at least two occasions, followed by evaluation of the cause.

As ovarian function becomes less predictable, estrogen and progesterone patterns change. The transition may affect temperature regulation, sleep, bleeding patterns, mood, cognition, vaginal and urinary comfort, sexual function, bone turnover, and body composition. Not every woman experiences the same cluster or severity.

Progesterone exposure often becomes less consistent as ovulation becomes irregular. Estrogen may fluctuate before settling at lower postmenopausal levels. This is one reason perimenopause can feel less like a smooth decline and more like an unpredictable signal.

The goal of care is not to recreate a laboratory profile from youth. It is to identify bothersome symptoms, protect relevant long-term health, and use the lowest effective, individualized approach when treatment is appropriate.

Menopausal hormone therapy is the most effective treatment for bothersome hot flashes and night sweats. It can also treat genitourinary symptoms, although low-dose local vaginal therapy may be sufficient when symptoms are limited to that area. Systemic therapy helps prevent bone loss while it is being used and can reduce fracture risk in appropriately selected women.

Hormone therapy is not a universal anti-aging treatment, a guaranteed treatment for weight loss, or a proven strategy for preventing every chronic disease. Sleep, mood, cognition, energy, and sexual function may improve when a hormone-responsive symptom is the true driver, but those outcomes are multifactorial.

The formulation, route, dose, timing, uterus status, and individual health history matter. A woman with a uterus who uses systemic estrogen generally needs adequate progestogen protection to reduce the risk of endometrial hyperplasia and cancer.

For more than two decades, public understanding of menopausal hormone therapy was shaped heavily by broad interpretations of the Women's Health Initiative. That trial provided important safety information, but its findings were often generalized to women of different ages, different times since menopause, and different formulations and routes.

In February 2026, the FDA approved labeling changes for six menopausal hormone therapy products that removed cardiovascular disease, breast cancer, and probable dementia statements from the boxed warning. Important precautions and product-specific risks remain, and the boxed warning concerning endometrial cancer with systemic estrogen used without adequate progestogen in a woman with a uterus was not simply erased.

The practical lesson is not that hormone therapy is risk-free. It is that age, timing, formulation, route, dose, and patient selection matter, and that older fear-based summaries are not an adequate substitute for an individualized discussion.

A history of hormone-sensitive cancer, unexplained vaginal bleeding, prior clotting events, stroke, significant cardiovascular disease, liver disease, pregnancy, and other conditions can change whether and how hormone therapy is considered. Family history, breast screening, blood pressure, migraine pattern, smoking, and medication interactions may also matter.

Route can influence risk. Transdermal estradiol avoids first-pass liver metabolism and may be preferred in some patients with metabolic or clotting considerations, but no route eliminates the need for screening and follow-up.

There are also effective nonhormonal options for vasomotor symptoms and other menopause concerns. Choosing not to use hormones is a legitimate medical decision, not a failure to optimize.

Testosterone treatment is appropriate for men with symptoms and signs of hypogonadism plus consistently and unequivocally low testosterone levels, after the cause has been evaluated. It should not be prescribed solely to improve appearance, athletic performance, or because a patient wants the highest possible number.

When the diagnosis is correct, treatment may improve sexual symptoms, anemia, bone density, or body composition in selected men. Response varies, and fatigue or erectile dysfunction may persist when sleep apnea, vascular disease, medication effects, depression, relationship factors, or another condition is the real driver.

Testosterone can suppress sperm production and fertility. It can raise hematocrit and requires monitoring. Prostate risk assessment, cardiovascular history, sleep apnea, urinary symptoms, and other contraindications or cautions must be reviewed.

Women also produce testosterone, and androgen levels change with age and ovarian function. Evidence supports carefully dosed testosterone therapy primarily for selected postmenopausal women with hypoactive sexual desire disorder after a complete biopsychosocial evaluation.

Testosterone is not an established general treatment for female energy, cognition, weight loss, or longevity. Dosing designed for men can cause acne, unwanted hair growth, scalp hair changes, voice changes, or other androgenic effects. When used, the goal is physiologic replacement with monitoring, not pushing levels above the female range.

Bioidentical describes a hormone that is chemically identical to one produced by the human body. FDA-approved estradiol and micronized progesterone are bioidentical. The term does not mean natural, risk-free, or superior simply because it appears on a label.

Compounded hormones can be useful when a patient has a legitimate need that an approved product cannot meet, such as a specific dosage form or ingredient avoidance. Compounded drugs are not FDA-approved, and consistency, potency, sterility, and evidence must be considered carefully. Whenever an FDA-approved option meets the clinical need, that regulatory oversight is meaningful.

The most important question is not whether a marketing term sounds reassuring. It is whether the product, dose, route, and monitoring plan are appropriate for the patient.

Hormonal changes can influence skin hydration, collagen, hair, muscle, fat distribution, and the way a patient recovers. That connection is real, but it does not make aesthetic procedures a substitute for medical care or hormone therapy a substitute for skincare, exercise, nutrition, and sleep.

A patient may benefit from both an aesthetic plan and medical evaluation, but each should stand on its own indication. I do not believe hormones should be prescribed simply to make someone look younger. I do believe that helping an appropriate patient sleep, maintain bone and muscle, improve sexual health, and feel like themselves can change how they experience aging.

The outside and inside are connected, but they should not be confused.

Hormone care is not a one-time prescription. Symptoms, side effects, blood pressure, bleeding patterns, laboratory values, cancer screening, fertility goals, and other relevant measures need follow-up. The exact monitoring depends on the therapy and the patient.

The best dose is not the highest dose or the dose that produces the most dramatic laboratory value. It is the lowest appropriate dose that achieves the clinical goal without creating unnecessary risk.

Sometimes treatment is adjusted. Sometimes another diagnosis is found. Sometimes the right decision is to stop. That ongoing reassessment is what makes hormone care medicine rather than a product sale.

Hormones can be an important part of why a patient feels different with age, but symptoms and laboratory values must be interpreted together. Treatment can be genuinely helpful when the diagnosis is sound, the goals are realistic, contraindications are respected, and monitoring is built into the plan.

The objective is not to chase youth or perfect numbers. It is to restore appropriate physiology where possible, address symptoms that matter, protect long-term health, and remain honest about what hormones can and cannot do.